martes, 30 de abril de 2019

More reads

The Readout
Damian Garde

More reads

  • The obscure advisory committees at the heart of the U.S. drug pricing debate. (Reuters)
  • A new Sun Pharma policy on insider trading raises questions of double standards. (STAT Plus)
  • How big tech is struggling with the ethics of AI. (Financial Times)
  • After amyloid failures, it’s time to take a new tack for treating Alzheimer’s. (STAT)

No hay comentarios:

Publicar un comentario